Xromi (hydroxycarbamide)
- Region
- 🇪🇺 EU
- Active substance
- hydroxycarbamide
- Company
- Lipomed GmbH
- Status
- Authorised
- Therapeutic area
- Anemia, Sickle Cell
- EU approval
- Mon 01 Jul 2019
- Application
- EMEA/H/C/004837
- ATC
- L01XX05
- Official record
- www.ema.europa.eu
Indication
Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Siklos Authorised · Theravia
Follow Xromi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.